Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners
Tribe Technology set to deliver healthy pipeline of orders from Tier-One minersView Video
Andrada Mining acquisition elevates the miner to emerging mid-tier status
Andrada Mining acquisition elevates the miner to emerging mid-tier statusView Video

Latest Share Chat

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Being bearish but also bullish on Europe Inc

Wed, 07th Dec 2022 11:22

STOXX 600 down 0.5%

*

U.S. banks warn of recession

*

GSK rallies as Zantac lawsuits dismissed

*

U.S. stock futures slip

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

BEING BEARISH BUT ALSO BULLISH ON EUROPE INC (1116 GMT)

Jefferies goes straight to point to highlight how different each European country equity market is, which in turns means the dispersion of returns in the region is going to vary widely.

"One size doesn't fit all," says Sean Darby, one of the bank's global equity strategists.

Darby and team in fact are bullish on countries like France and the UK, modestly bullish on Germany, while at the same time, they're bearish on Poland and modestly so for Italy.

"European bourses are far from homogenous, so the dispersion of equity returns in 2023 will be quite wide," they say.

Bringing all together though, they see gains for the Euro STOXX betting that lead indicators will bottom out in the first half of 2023, followed by earnings revisions with a 3-month lag.

"There is room for the index to climb by ~12% as interest rates are likely to peak in 1Q23. This would leave the index trading on 480," they write.

EUROPEANS JUST LOVE GOOGLE (1039 GMT)

Growth stocks have been all the rage over the past few years, at least until late 2020, when it became apparent that the world economy was recovering and inflation was - at least at that point - ticking up at a comfortable pace. But once rates started rising and inflation began to rip higher, value stocks, which are more closely linked to the underlying economy, reemerged as a top pick. This year, European value stocks, which include the likes of energy, natural resources and autos, have gained 1.7%, compared with a drop of nearly 14% in growth stocks and an 11% fall in the broader STOXX.

In terms of what would-be European investors are interested in, the answer is clear, according to data from retail investing company CMC Markets. "Google" is the most searched-for growth stock in the region, topping the charts in 27 countries, with Meta's "Facebook" a close second, coming out on top in 20 countries. The number of searches varies depending on the population. Germany is the country with the highest number of searches a month and "Google" is the most popular, with 149,000 searches. The Netherlands is second, with 115,000 searches. Ukraine is the country with the most searches for "Facebook", with 107,000 searches a month, followed by the UK and France, with 87,000 and 86,000 searches, respectively.

"Google and Facebook are dominating as the most popular growth stocks across Europe. Both of these companies have a huge influence on the market, and the media, which is why many Europeans are looking to invest in them," Michael Hewson, chief market analyst at CMC Markets said.

FORZA ITALIA IN EARLY EUROPE (0915 GMT)

Italy may not have made it to the soccer World Cup, but Milan blue-chips are leading the way this morning, as European equities trade in a sea of red so far. The FTSE MIB is up 0.6%, by far the best performing index in the region, compared with a 0.1% loss in the broader STOXX 600 index, and well beyond Stockholm's 0.5% loss. Utility company ENEL is leading its sector higher and is up 1.5%, making it one of the biggest positive weights on the STOXX and lender UniCredit is up 1.8%.

But today belongs to the pharma and biotech sector, which is the standout gainer, up 1% thanks to a surge in shares of UK drugmaker GSK following a U.S. ruling that dismissed thousands of lawsuits claiming that over-the-counter heartburn medication Zantac causes cancer. The stock rose as much as 15% earlier on and, with a 10% gain, is on track for its largest one-day rise since 1998. French rival Sanofi, which is also part of the suit, is up 5.7%. All the drugmakers involved denied Zantac caused cancer.

HAT-TRICK (0755 GMT)

While European shares ended lower for the third straight session on Tuesday, spooked by recession worries, another hat-trick dominated the World Cup a few hours later.

Three goals by Portugal's 21-year-old Goncalo Ramos against Spain in his first World Cup sent his side through to the quarter-finals for the first time in 16 years. And a 3-0 shootout win by Morocco against former champions Spain meant that Morocco became the first Arab nation ever to qualify for the tournament's quarter-finals.

In the arena of European stocks, there seem to be little excitement for risky assets on Wednesday, with Asian equities trading rangebound after U.S. stocks again suffered losses as markets gradually factor in sharper interest rates hikes.

For the euro zone, commentary by officials is hinting at a peak in rates but anaemic growth and stubbornly high inflation are haunting investors.

ECB policymaker Constantinos Herodotou said on Tuesday that interest rates will go up again but are now "very near" their neutral level.

Markets will focus on industrial output data due from Germany, while euro zone third-quarter GDP and employment numbers, and UK house prices are among the other economic indicators for the day.

Euro zone government bond yields dropped for the first time in three days on Tuesday in the run-up to a raft of major central bank decisions next week.

A Reuters poll of market strategists expect the dollar to rebound against most currencies over the coming months, with the growing threat of recession in the U.S. and elsewhere keeping it firm in 2023 through safe-haven flows.

On Tuesday, top bankers from JPMorgan Chase & Co, Bank of America and Goldman Sachs warned of a recession next year, as inflation threatens consumer demand.

On the corporate front, Airbus gave up a numerical forecast for jet deliveries and a date for its key production goal but retained its financial targets as it limped towards the end of a year battered by disruptions in factories and supply chains.

And British Prime Minister Rishi Sunak's government said it would ease restrictions on building onshore wind farms, heading off a revolt by his party's lawmakers who had demanded they should be permitted with local support.

Key developments that could influence markets on Wednesday:

Economic data: Germany Oct industrial production, Euro zone Q3 GDP, employment (final), UK Nov Halifax house prices

Speakers: ECB's Philip Lane, Elizabeth McCaul and Fabio Panetta

More News
10 Nov 2022 16:34

Sanofi, GSK score late win with EU COVID booster approval

Nov 10 (Reuters) - Sanofi said on Thursday it won European Union approval for its COVID-19 vaccine booster, jointly made with British partner GSK, after a drawn-out development effort that saw the pair fall behind now-dominant vaccine suppliers.

Read more
4 Nov 2022 07:00

Sanofi, Astra win EU approval for prevention of infant RSV

Nov 4 (Reuters) - The European Commission on Friday approved Sanofi and AstraZeneca's Beyfortus for the prevention of a common and highly contagious type of respiratory infections in infants.

Read more
2 Nov 2022 15:47

New GSK maintains strong start, but Zantac litigation looms large

Q3 profit, sales beat expectations

*

Read more
29 Sep 2022 11:44

Oddo BHF flags European pharma's attractive growth profile, prefers Novo Nordisk, AstraZeneca

Read more
26 Sep 2022 15:22

GSK selects Burberry's Brown as its first female CFO

Brown to join GSK in April

*

Read more
20 Sep 2022 08:58

Haleon believes it is not liable for any potential Zantac liabilities

LONDON, Sept 20 (Reuters) - Haleon believes it is not liable for any claims that may arise from U.S. litigation over the heartburn drug Zantac, the London-listed company's CEO Brian McNamara told Reuters on Tuesday.

Read more
20 Sep 2022 07:14

Haleon rejects Zantac indemnification requests from GSK, Pfizer

LONDON, Sept 20 (Reuters) - Haleon on Tuesday said it had notified GSK and Pfizer that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac.

Read more
5 Sep 2022 15:24

Sanofi sees EU regulatory decision on its COVID booster in weeks

BRUSSELS, Sept 5 (Reuters) - The European Union's drugs regulator may be a few weeks from deciding whether to approve the experimental COVID-19 vaccine developed by French drugmaker Sanofi and its British partner GSK, a Sanofi executive said on Monday.

Read more
30 Aug 2022 17:14

European stocks fall for third day as rate hike, recession fears grow

Aug 30 (Reuters) - European shares ended lower on Tuesday, failing to shrug off fears of higher interest rates amid a burgeoning energy crisis and looming recession.

Read more
17 Aug 2022 18:10

Sanofi trial failure halts work on breast cancer treatment amcenestrant

Aug 17 (Reuters) - Sanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare company's development prospects.

Read more
17 Aug 2022 17:22

European shares slip on inflation worries, Germany leads fall

Aug 17 (Reuters) - European shares slid on Wednesday and bond yields rallied after a sharp rise in UK inflation brought the spotlight back to more monetary tightening amid data which showed euro zone economic growth was slightly less robust in the second quarter.

Read more
17 Aug 2022 15:15

Plaintiff in first Zantac lawsuit set for trial drops case

Aug 17 (Reuters) - The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.

Read more
17 Aug 2022 08:21

GSK shares ease after plaintiff in first Zantac lawsuit drops case

LONDON, Aug 17 (Reuters) - Shares in GlaxoSmithKline fell slightly in early trading on Wednesday but stayed above recent lows after the plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial agreed to drop his case.

Read more
15 Aug 2022 22:17

UK first to approve Omicron COVID shot with Moderna nod

LONDON, Aug 15 (Reuters) - Britain, the first country to approve a coronavirus vaccine in late 2020, has now also given the first green light to a variant-adapted shot that targets both the original and Omicron version of the virus.

Read more
12 Aug 2022 17:17

European shares rise as healthcare, leisure stocks gain

Aug 12 (Reuters) - European shares rose on Friday after drugmakers rebounded following a slump in the previous session, and Flutter fanned a rally in the travel and leisure sector after an upbeat earnings forecast.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.